ESCRS Winter Meeting

ESCRS Winter Meeting

February 20, 2014
1 min read
Save

New aberrometer provides good outcomes in myopic LASIK

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Ljubljana, SLOVENIA — The new iDesign aberrometer is an effective, safe and reliable tool for treatment planning, providing good refractive outcomes and postoperative higher-order aberration results, according to one surgeon.

“The iDesign (Abbott Medical Optics) provides an innovative approach, with five measurements taken within a single capture sequence, including autorefraction, wavefront aberrometry, corneal topography, keratometry and pupillometry. Additional features are the high resolution Hartman-Shack wavefront sensor and the high measurement range between –16 D and +12 D, cylinder up to 8 D and [higher-order aberrations] up to 8 µm [root mean square],” Sarah Moussa, MD, said at the winter meeting of the European Society of Cataract and Refractive Surgeons.

Sarah Moussa

At the University of Salzburg, 200 myopic eyes of 110 patients were treated using the iDesign software coupled with the AMO Star S4 IR excimer laser for LASIK. Mean preoperative manifest refraction spherical equivalent was –5 D and mean cylinder was –1 D.

“Within our 2 months of follow-up, 100% of the eyes achieved attempted correction within 0.5 D and 96% were within 0.25 D. All patients achieved 20/25, 99% were 20/20, and 39% achieved 20/12 or better. Nearly half of the eyes gained at least one line, 44% were stable, and 5% gained two lines. Residual cylinder was between 0 D and 0.25 D at 2 months in 96% of the eyes,” Moussa said.

Total root mean square decreased significantly over the 2-month period, she said. Higher-order aberrations were stable. Spherical aberration decreased slightly until 1 week and was back to preoperative value at 2 months.

Disclosure: Moussa has no relevant financial disclosures.